CellMax Life Announces Expansion of Company Board With Leading Industry Experts
Renowned industry experts join to aid in preparation around premarket approval for FirstSight
SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena.
"Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of the most successful innovators and leaders in cancer diagnostics, and it is a privilege to have him join CelMax's advisory board. Ron's scientific expertise and extensive background in commercializing diagnostic tests will greatly enable execution of the regulatory and marketing strategies for our FirstSight colorectal cancer screening blood test."
Each new board member brings a wealth of experience:
- Stan Lapidus is an inventor and entrepreneur who currently serves on a number of healthcare and medical technology boards. He was the founding CEO of three medical diagnostics companies: Cytyc Corp., acquired by Hologic Inc. (NASDAQ:HOLX), which revolutionized early detection of cervical cancer, and Exact Sciences (NASDAQ: EXAS), which pioneered the noninvasive early detection of colorectal cancer. He holds 37 patents, primarily in methods for early detection of cancer, and served as an instructor at MIT where he taught graduate-level courses on clinical trials. The two ThinPrep prototypes developed at Cytyc are displayed at the Smithsonian National Museum of American History.
- Ron Andrews has more than 35 years of experience in the diagnostics industry. He served as CEO of two precision diagnostic companies, Clarient Inc., acquired by GE Healthcare, and Oncocyte Corp., and held corporate leadership positions at ThermoFisher/Life Technologies, Roche Molecular Diagnostics, and GE Healthcare. Through these experiences, Ron brings deep expertise in commercializing molecular diagnostics and is a dynamic and respected leader in the medical device industry.
"I've spent most of my career focused on the early detection of cancer and am excited and impressed by CellMax Life's progress with its FirstSight blood test," said Stan Lapidus. "The recent study data at ASCO GI 2023 displays the technology platform's unique ability to detect colorectal cancer and advanced adenomas with a high degree of sensitivity, which is critical to the ultimate goal of eradicating this preventable cancer."
"Colorectal cancer is one of the most preventable cancers, yet it is the second most common cause of death. A noninvasive screening blood test that detects both colorectal cancer and advanced adenomas has the potential to increase patient adherence for screening and in turn, decrease both incidence and mortality," said Ron Andrews. "Being able to have a hand in the regulatory approval pathway for FirstSight, which has demonstrated high sensitivity in an intended use population, solidified my personal commitment to the company and its mission to change how we detect and manage cancer."
For more information about CellMax Life and its FirstSight test, visit cellmaxlife.com.
About CellMax Life:
CellMax Life is a diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California. For more information, visit http://www.cellmaxlife.com.
Media Contact
Stephen Su, Cellmax Life, 1 408-887-7640, [email protected]
SOURCE Cellmax Life
Share this article